In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter. Ozempic was approved by the FDA in 2017 to treat people with Type 2 diabetes who risk serious health consequences without medication. Recently, there has been a spike in demand for Ozempic, or semaglutide, due to its weight loss benefits, which has led to shortages. Some doctors prescribe Ozempic off-label to treat obesity. (Photo illustration by Mario Tama/Getty Images)
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles, cannot seem to shed the pounds hurting their health.
“They have a tremendous amount of disease burden,” said Ro, medical director of the University of North Carolina Physicians Network weight management program, which serves patients from marginalized communities at clinics across the state. “All the complications that you could think of.”
But the increasingly popular drug therapy known as GLP-1s could help, she said.
GLP-1 drugs mimic a hormone in the intestinal tract to balance the body’s blood sugar levels. And while GLP-1 drugs such as Ozempic, Wegovy and Zepbound have been around for years to help patients with diabetes, they are growing in popularity to treat patients in need of significant weight loss. That’s because the drugs also send the brain a signal that reduces hunger.
Due to their high list price in the United States — ranging from about $940 to $1,350 a month before insurance, rebates or discounts — many patients can’t afford them. (And weight loss is not a federally approved use of Ozempic, despite its popularity, though similar drugs of different dosages are approved for obesity treatment.)
But now that these drugs are in greater demand from both patients and doctors, state Medicaid programs are grappling with whether to cover them for weight loss, both for reasons of equity and to save on future health expenditures.
Some researchers, however, question whether the drugs can help lower costs in the long run.
‘Compounded’ weight-loss drugs are a growing problem for state regulators
Last August, North Carolina began covering some federal Food and Drug Administration-approved GLP-1s for obesity treatment among some populations.
South Carolina followed on Nov. 1. But prior authorization is required for coverage.
To have the drugs paid for by Medicaid, patients must participate in dietary counseling and have a body mass index exceeding the obesity threshold, along with related health problems. And their doctor must attest they are increasing their physical activity, according to the South Carolina Department of Health and Human Services.
“Coverage of GLP-1 drugs is a component of the agency’s broader anti-obesity initiative, which also includes increased coverage of nutritional counseling,” spokesman Jeff Leieritz told the SC Daily Gazette.
The agency expects the dual initiative — drugs and counseling — to cost the state $3.3 million annually, he said.
At least 12 other states cover GLP-1s for obesity treatment.
“For me, it wasn’t ever an option not to cover it,” said Kody Kinsley, who just ended his term as secretary of the North Carolina Department of Health and Human Services under former Democratic Gov. Roy Cooper.
“The first big reason was just a sense of doing what is right for folks,” Kinsley told Stateline. He also thinks coverage is the right investment economically, estimating that the North Carolina Medicaid program spends about a billion dollars a year on obesity-related expenses.
He told Stateline that funding drugs that can cut those costs down by even a small percentage is worth it over the long run. He also noted that Medicaid covers other expensive drugs. The department expects the cost of covering GLP-1s to be about $16 million a year under the new policy.
By comparison, coverage for Dupixent, a drug commonly used to treat eczema, runs North Carolina about $28 million a year.
“It is my experience that the only time we seem to really get up in arms as a society about the cost of a drug — to the point where we are willing to not cover it — is when it is for some sort of stigmatized disease,” Kinsley told Stateline.
Obesity, he noted, is a recognized medical condition.
Medicaid spending
Medicaid programs cover some GLP-1 drugs to treat obesity in a dozen other states: California, Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, New Hampshire, Pennsylvania, Rhode Island, Virginia and Wisconsin.
According to a report from the health policy research organization KFF released in November, half of the remaining state Medicaid programs are considering covering the drugs, but the high costs are still prohibitive for most despite federal matches and rebate programs with drug manufacturers.
For me, it wasn’t ever an option not to cover it.
– Kody Kinsley, former secretary of the North Carolina Department of Health and Human Services
State officials say health equity — the idea that all groups regardless of background deserve equal access to health care — is one of the main reasons they are considering the coverage, but they worry higher costs will put pressure on their Medicaid budgets, said KFF senior policy analyst Liz Williams, who co-authored the survey of state Medicaid program directors.
Medicaid spending on GLP-1s for all conditions increased from $597.3 million for about 755,000 prescriptions in 2019, to $3.9 billion for 3.8 million prescriptions in 2023, according to KFF.
It’s hard to tell, however, how much of the increase is solely for obesity vs. diabetes, or a combination of both, the study noted.
Some states in KFF’s survey said they are considering whether coverage expansion in the future may reduce long-term Medicaid spending on chronic illnesses such as diabetes and heart disease.
Angry patients spur new state watchdogs to bring down drug prices
But one researcher, John Cawley, a professor of economics and public policy at Cornell University, and his colleagues found that while obesity “basically doubles a person’s annual health care costs,” the savings associated with public insurance plans covering GLP-1s for just obesity treatment are dependent on the patient’s starting body mass index, or BMI.
A healthy weight is a BMI of up to 25. People who are obese, based on their height and weight, have an amount of fat on their bodies representing a BMI of 30 or higher.
“You shouldn’t expect to see almost any cost savings for somebody whose BMI is around 30 or 31,” Cawley told Stateline. He noted that most significant savings would happen at a starting BMI of around 40, but added that “those savings still may not be great enough to pay for the current list price of these drugs.”
Cawley said there are numerous other reasons to cover the drug, though, such as improving someone’s quality of life.
An ‘obesogenic environment’
Ro, the weight management doctor, told Stateline that across North Carolina, people in vulnerable communities can be predisposed to developing obesity because they often live within what’s known as an “obesogenic environment” — a combination of physical, economic and social factors that promotes obesity.
Residents struggle with losing weight not only due to a diet of unhealthy foods, but also because of generational genetics, a dearth of grocery stores with healthy foods, and busy schedules with multiple jobs and a lack of child care. Many cities in the state aren’t that “walkable,” leaving many residents with few options for basic exercise.
And some of the state’s most popular foods are high-fat, high-sugar dishes such as pork shoulder slathered in sugary and smoky barbecue sauce, peach cobbler, fried shrimp and fried green tomatoes. North Carolina is the “buckle of the barbecue belt,” Kinsley said.
There, 70% of residents are either overweight or obese. Obesity is linked to several comorbidities, such as diabetes and heart failure. The federal Centers for Disease Control and Prevention estimates that 34% of North Carolina adults — compared with 40% nationally — are obese.
That rate rises across demographic groups. While white North Carolinians experience an obesity rate of 32%, Hispanic populations sit at 34%, Indigenous North Carolinians are at 38%, and Black North Carolinians have a rate of 48%.
Most Medicaid enrollees in the state are people of color.
South Carolina’s obesity rate is worse than its northern neighbor’s, at 36% of all adults, according to 2023 data from the CDC, the most recent available.
New SC group pushes for Medicaid expansion, pointing to NC as example
In late November, the Biden administration proposed a new rule to require Medicaid and Medicare programs to cover GLP-1s for weight loss. The incoming Trump administration will have to decide whether to approve those changes.
The Biden administration estimates that the change would cost the federal government about $11 billion over the course of 10 years for Medicaid. States would have to pay an estimated $3.8 billion.
But the drugs aren’t without dangers of their own.
Common side effects of Wegovy, according to its website, include nausea, diarrhea, vomiting and dizziness. Possible serious side effects include low blood sugar (hypoglycemia), pancreatitis, kidney failure, and thyroid tumors.
(While Ozempic, which lists the same possible side effects, is the most known GLP-1 drug, it’s not FDA approved for weight loss generally, which is a common misconception. It’s approved only for patients with Type 2 diabetes. Wegovy, however, is among GLP-1s approved for obesity treatment.)
While states assess their capacities and the federal government considers its plans, Ro said her patients are getting a better shot at getting healthier by having access to the coverage.
“GLP-1s are not the answer for everybody,” Ro told Stateline. “But If I have a high-risk patient with heart disease, with sleep apnea and advanced liver disease, this could be a lifesaving medication.”
SC Daily Gazette reporter Skylar Laird contributed to this report.
Like the SC Daily Gazette, Stateline is part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity. Stateline maintains editorial independence. Contact Editor Scott S. Greenberger for questions: info@stateline.org.